Abstract
Abstract Rheumatoid arthritis (RA) is one of the inflammatory joint diseases in a heterogeneous group of disorders that share features of the destruction of the extracellular matrices of articular cartilage and bone. Matrix metalloproteinase (MMP) enzymes (in particular MMP9), are crucial for RA. Given the limited investigation of the MMP9 inhibition by coumarin derivatives, the present study was taken up. A coumarin derivative (ethyl 6-[(4-methyl-2-oxo-2H-chromen-7-yl)oxy]hexanoate) was synthesized, characterized by spectral analysis (1HNMR, 13CNMR, IR, and MS), single crystal XRD and molecular docking was carried out. The title compound C18H22O5 crystallizes in the monoclinic crystal system in P21/c space group. The glide docking score for the title compound is -6.8, compared with -6.6 for co-crystal compound (LT4). The synthesis, characterization and crystal data are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
